Robert Szpera

Robert Szpera

Auto-generated profile, based on publicly available information

Robert Szpera

Chemical Research and Development, Pfizer Inc., Groton, Connecticut 06340, United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2021 in The Journal of Organic Chemistry
Verified
Journal Article
Closed access
DWDavid E. Wheatley
David E. Wheatley
CFClement Q. Fontenelle
Clement Q. Fontenelle
RKRamakrishna Kuppala
Ramakrishna Kuppala
RSRobert Szpera
Robert Szpera
EBEdward L. Briggs
Edward L. Briggs
BLBruno Linclau
Bruno Linclau

7 December 2024 in Organic Process Research & Development
Verified
Journal Article
Closed access
DBDavid J. Bernhardson
David J. Bernhardson
AHAran K. Hubbell
Aran K. Hubbell
RSRobert A. Singer
Robert A. Singer
RSRobert Szpera
Robert Szpera
STSergei Tcyrulnikov
Sergei Tcyrulnikov
CAChristophe Allais
Christophe Allais

27 December 2017 in Beilstein Journal of Organic Chemistry
Verified
Journal Article
Open access
PDF file
RSRobert Szpera
Robert Szpera
NKNadia Kovalenko
Nadia Kovalenko
KNKalaiselvi Natarajan
Kalaiselvi Natarajan
NPNina Paillard
Nina Paillard
BLBruno Linclau
Bruno Linclau
The diastereoselective synthesis of fluorinated building blocks that contain chiral fluorine substituents is of interest. Here we describe optimisation efforts in the synthesis of anti-2,3-difluorobutane-1,4-diol, as well as the synthesis of the corresponding syn-diastereomer. Both targets were synthesised using an epoxide opening strategy.

28 May 2024 in Organic Process Research & Development
Verified
Journal Article
Closed access
RSRobert Szpera
Robert Szpera
SHShanjun Huang
Shanjun Huang
HFHarriet A. M. Fenton
Harriet A. M. Fenton
WWWilliam Waddington
William Waddington
AGAdam E. S. Gymer
Adam E. S. Gymer
FGFrank Gupton
Frank Gupton

30 January 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
RSRobert Szpera
Robert Szpera
SHShanjun Huang
Shanjun Huang
HFHarriet A. M. Fenton
Harriet A. M. Fenton
WWWilliam Waddington
William Waddington
AGAdam E. S. Gymer
Adam E. S. Gymer
FGFrank Gupton
Frank Gupton
Nirmatrelvir is an inhibitor of SARS-CoV-2 main protease and is the active ingredient in PaxlovidTM. Nirmatrelvir presents a significant synthetic challenge, in no small part due to a cost-driving lactam containing fragment with two stereogenic centers. Our goal was to help decrease the cost of nirmatrelvir, by developing a scalable low-cost synthesis of this fragment, avoiding use of cryogenic conditions reported in the initial route. Herein we disclose three catalytic asymmetric routes to-wards this fragment, via i) chiral Lewis acid (copper) catalysis, ii) chiral Brønsted base organocatalysis and iii) chiral bifunctional hydrogen-bond-donor organocatalysis.